(Q28279108)

1

0 references

Dietmar Winkler

object named as

Dietmar Winkler

2

0 references

author name string

Anastasios Konstantinidis

3

0 references

Matthäus Willeit

4

0 references

Nicole Praschak-Rieder

Phototherapy in individuals with and without subsyndromal seasonal affective disorder.

5

0 references

language of work or name

English

0 references

publication date

March 2007

0 references

published in

Psychopharmacology

0 references

volume

190

0 references

issue

4

0 references

page(s)

575-9

0 references

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-006-0645-3

Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-006-0645-3

Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus

21 January 2018

1 reference

12 December 2020

Melatonin secretion in SAD patients and healthy subjects matched with respect to age and sex.

1 reference

12 December 2020

Dim light melatonin onset and circadian temperature during a constant routine in hypersomnic winter depression

1 reference

12 December 2020

Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour

1 reference

12 December 2020

Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy

1 reference

12 December 2020

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

1 reference

12 December 2020

The Hamilton depression scale. Evaluation of objectivity using logistic models

1 reference

12 December 2020

Escitalopram in Seasonal Affective Disorder: Results of an Open Trial

1 reference

12 December 2020

Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

A forced desynchrony study of circadian pacemaker characteristics in seasonal affective disorder

1 reference

12 December 2020

Diurnal and seasonal rhythms of melatonin, cortisol and testosterone in interior Alaska

1 reference

12 December 2020

Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat.

1 reference

12 December 2020

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

1 reference

12 December 2020

Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder

1 reference

12 December 2020

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

1 reference

12 December 2020

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms

1 reference

12 December 2020

Treatment of seasonal affective disorder

1 reference

12 December 2020

Bright light therapy in seasonal affective disorder – does it suffice?

1 reference

12 December 2020

Melatonin sensitivity to dim white light in affective disorders

1 reference

12 December 2020

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

12 December 2020

Melatonin treatment of winter depression: a pilot study

1 reference

12 December 2020

Novel naphthalenic ligands with high affinity for the melatonin receptor

1 reference

12 December 2020

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

12 December 2020